Seiichi Inamura

Head of Search and Evaluation Group at Chugai Pharmaceutical Co., Ltd.

Presenter

Chugai, a member of Roche group, is a Japanese company focused on creating innovative medicinal products which address unmet medical needs. Our innovative antibody technologies have led to multiple therapeutics helping patients around the world. We also establiched orally available mid-size molecule, such as cyclic peptide, as for new platform technology. We are the leaders in oncology therapeutics in Japan and have an overall top-level presence in the Japanese pharmaceutical industry. Our proprietary products, discovered and developed by Chugai, include the anti-IL-6 monoclonal antibody Actemra®/RoActemra® (tocilizumab), ALK inhibitor Alecensa® (alectinib) and anti-FlXa/FX bispecific antibody Hemlibra® (emicizumab), all of which are approved worldwide and illustrate our robust drug R&D capabilities. Chugai is keen to collaborate with companies with innovative drug discovery technologies. As well, we seek clinical stage licensing opportunities in the oncology, ophthalmology, neuroscience, immunology and CVRM areas. Further, Chugai Pharma Europe (CPE) Ltd. is Chugai’s European presence for development, regulatory, sales and marketing of pharmaceutical products through subsidiaries located in the UK, France, and Germany. CPE is commercializing products together with Roche in the indications of oncology, rheumatology and haemophilia. CPE seeks late-stage and commercial in-licensing business opportunities in those indications, as well as cancer supportive care and orphan diseases.